← Archive

Business

Monday, 26 January 2026

Gold prices exceed ₹1,60,000 per 10 grams in India

Gold prices exceed ₹1,60,000 per 10 grams in India

Gold prices surged past ₹1,60,000 per 10 grams in India, with 24-carat gold reaching ₹1,60,410 in New Delhi on January 25, 2026, marking a significant weekly increase of ₹16,480. The rise is attributed to strong global cues, record international prices, and expectations of US Federal Reserve rate cuts, as spot gold also hit $4,967.41 per ounce amid growing economic uncertainty.

Copper prices soar amid AI demand and supply concerns

Copper prices soar amid AI demand and supply concerns

Copper prices have reached an all-time high as investors anticipate increased demand driven by artificial intelligence applications, despite a slowdown in China's economy. A report by S&P Global warns of a potential supply shortfall, projecting global copper demand will rise by 50% from 28 million tonnes in 2025 to 42 million by 2040, with a possible supply gap of 10 million tonnes by the end of the next decade if new mining investments are not made.

Bangladesh's Power Sector Faces Billions in Extra Costs

Bangladesh's Power Sector Faces Billions in Extra Costs

A review has revealed that electricity deals signed with Adani Power and other companies during Sheikh Hasina's 15-year tenure have resulted in billions of dollars in additional costs for Bangladesh's power sector. This finding comes amid ongoing concerns about the country's energy management and the impact of these agreements on consumer prices.

Merck ends negotiations to acquire Revolution Medicines

Merck ends negotiations to acquire Revolution Medicines

Merck has terminated its negotiations to acquire Revolution Medicines, a deal that could have been valued between $28 billion and $32 billion, according to reports. The discussions faltered over pricing disagreements, although there remains a possibility for future talks or interest from other potential buyers. Revolution Medicines, which has a market capitalization of approximately $22.7 billion, is developing the experimental cancer drug daraxonrasib, currently in late-stage trials.

Your daily briefing — completely free

One email per day. Unsubscribe anytime.